ASTH
Astrana Health·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Significant Net Income Decline
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ASTH
Astrana Health, Inc.
A leading physician-centric, technology-powered, risk-bearing healthcare management company
Healthcare Providers and Services
11/01/1985
12/08/2017
NASDAQ Stock Exchange
1,900
12-31
Common stock
1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801
--
Astrana Health, Inc., was incorporated in Delaware on November 1, 1985. Astrana is a patient-centered, doctor-centered comprehensive medical services company with a management team of over ten years of work experience to provide coordinated, cost-effective medical services based on. Astrana has established a company and culture that focuses on physicians providing quality care services to patients, population health management and care coordination, especially for elderly patients and conditions with multiple chronic diseases. Astrana operates in a reporting division in the field of medical services, as well as implementing and operating Innovative Medical models to build patient-centric, doctor-centric experiences.
Earnings Call
Q1/2025
Estimate EPS0.33
Actual EPS0.14
Estimate Revenue630.68M
Actual Revenue620.39M
Astrana's Q1 2025: Contradictions on Medicaid Trends, Revenue Growth, and Prospect Integration
May 19,2025 03:26
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.61
Actual EPS0.01
Estimate Revenue952.83M
Actual Revenue956.05M
Astrana Health's Q3 2025: Contradictions Emerge on Medicaid Costs, Prospect Health Integration, and EBITDA Impact
Nov 09,2025 08:10
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ASTH has released its 2025 Q3 earnings. EPS was reported at 0.01, versus the expected 0.61, missing expectations. The chart below visualizes how ASTH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ASTH has released its 2025 Q3 earnings report, with revenue of 956.05M, reflecting a YoY change of 99.71%, and net profit of 1.08M, showing a YoY change of -94.33%. The Sankey diagram below clearly presents ASTH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
